BRONKOMETER
Clinical safety rating
cautionComprehensive clinical and safety monograph for BRONKOMETER (BRONKOMETER).
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
| Metabolism | Metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). |
| Excretion | Renal: 10-15% unchanged; 70-80% as sulfate conjugates; biliary/fecal: <5%. |
| Half-life | Terminal elimination half-life: 2-3 hours; clinically, bronchodilation persists but dosing interval is 3-4 hours due to rapid onset and offset. |
| Protein binding | 50-60% bound primarily to albumin. |
| Volume of Distribution | Vd: 1-2 L/kg; indicates extensive distribution into tissues including lungs. |
| Bioavailability | Aerosol: 10-20% lung deposition; remainder swallowed with negligible oral bioavailability due to first-pass metabolism. |
| Onset of Action | Inhalation: 1-5 minutes. |
| Duration of Action | 3-4 hours; may be shorter with severe bronchospasm. |
| Molecular Weight | 239.31 |
Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No specific dose adjustment required based on GFR; clinical monitoring advised in severe renal impairment due to potential for drug accumulation. |
| Liver impairment | No formal Child-Pugh based modifications established; caution in severe hepatic impairment due to possible altered metabolism. |
| Pediatric use | Children 6-12 years: 1-2 inhalations every 4 hours as needed; <6 years: not recommended due to limited data. |
| Geriatric use | Initiate at lower end of dosing range (1-2 inhalations every 4 hours as needed) due to increased sensitivity and concomitant comorbidities; monitor for adverse cardiovascular effects. |
| 1st trimester | Isoetharine (active ingredient) is a beta-2 adrenergic agonist. Limited human data; animal studies show no consistent teratogenic effects. Use only if clearly needed. |
| 2nd trimester | Beta-2 agonists may cause maternal tachycardia and uterine relaxation. Use with caution; monitor maternal heart rate and uterine activity. |
| 3rd trimester | Risk of neonatal hypoglycemia and tachycardia if used near term. Avoid prolonged use; consider alternative bronchodilators. |
Clinical note
Comprehensive clinical and safety monograph for BRONKOMETER (BRONKOMETER).
| Placental transfer | Isoetharine is a small molecule and likely crosses the placenta. Degree of transfer not well quantified but expected based on lipophilicity and molecular weight. |
| Breastfeeding | Excretion into breast milk is unknown. Given short half-life and low oral bioavailability, exposure to infant is likely minimal. Use with caution in breastfeeding women, especially if high doses are required. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Insufficient human data; animal studies show no teratogenic effects at clinically relevant doses. Risk cannot be excluded; use only if clearly needed. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and serum glucose; fetal heart rate monitoring if used during labor. |
| Fertility Effects | No known adverse effects on fertility in humans; animal studies not suggestive of impairment. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to isoetharine or any componentCardiac arrhythmias associated with tachycardiaSevere hypertensionPheochromocytoma
| Precautions | Paradoxical bronchospasm may occur, Cardiovascular effects including increased heart rate and blood pressure, Hypokalemia may occur, Use with caution in patients with cardiovascular disorders, hyperthyroidism, diabetes, or seizure disorders, Excessive use may lead to tolerance |
| Food/Dietary | Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase cardiac stimulation. No specific food restrictions, but a balanced diet is recommended. Avoid alcohol as it may worsen side effects. |
| Clinical Pearls | Bronkometer contains isoetharine, a beta-2 selective agonist, but less selective than albuterol. It is rarely used now due to higher cardiac side effect risk. Monitor for paradoxical bronchospasm; discontinue if occurs. Use with caution in patients with hyperthyroidism, diabetes, or hypertension. |
| Patient Advice | Shake the inhaler well before each use. · Prime the inhaler by spraying 4 test sprays into the air away from face if new or not used for 3 days. · Exhale fully, then place mouthpiece in mouth and inhale slowly while pressing down on canister. · Hold breath for 10 seconds, then exhale slowly. · Wait at least 1 minute between puffs. · Rinse mouth with water after use to prevent mouth irritation. · Seek emergency care if you experience worsening shortness of breath, chest pain, or irregular heartbeat. |
Loading safety data…